Oral iron chelators - Development and application

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 2, 2002, Pages 369-384

  Liu, Ding Y ^a   Liu, Zu D ^a   Hider, Robert C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Iron chelation therapy; Iron chelator

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; 2 ETHYL 3 HYDROXY 1 (2 HYDROXYETHYL) 4 PYRIDINONE; 3 HYDROXY 1 (3 HYDROXYPROPYL) 2 METHYL 4 PYRIDINONE; 3 HYDROXY 4 PYRIDONE DERIVATIVE; 3 HYDROXYPYRIDINONE; 4 [3,5 BIS (HYDROXYPHENYL) 1,2,4 TRIAZOL L YL] BENZOIC ACID; ARACHIDONATE 5 LIPOXYGENASE; CP 251; CP 361; CP 502; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFERRIFERRITHIOCIN; ENTEROCHELIN; FERRIPOX; FERRITIN; ICL 6702; IRON; IRON CHELATING AGENT; IRON COMPLEX; ISONIAZID; LIGAND; N,N' BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; OXYGENASE; PRODRUG; PYRIDONE DERIVATIVE; PYRIDOXAL ISONICOTINOYLHYDRAZONE; SIDEROPHORE; TRIAZOLE DERIVATIVE; TRIS(2,3 DIHYDROXYBENZYL) 1,3,5 TRIS (AMINOMETHYL)BENZENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; 3 HYDROXY 4 PYRIDONE; LIPOXYGENASE; N,N' BIS(2 HYDROBENXYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; PYRIDOXAL ISONICOTINOYL HYDRAZONE; RIBONUCLEOTIDE REDUCTASE; TRIS(2,3 DIHYDROXYBENZYL) 1,3,5 TRIS(AMINOMETHYL)BENZENE;

AGRANULOCYTOSIS; ARTHRALGIA; BETA THALASSEMIA; BINDING AFFINITY; BLOOD TRANSFUSION; CHELATION THERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; GASTROINTESTINAL ABSORPTION; HUMAN; IRON CHELATION; IRON METABOLISM; NAUSEA; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; REVIEW; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EXCRETION; DRUG PENETRATION; DRUG STABILITY; DRUG TRANSPORT; ENZYME INHIBITION; GLUCURONIDATION; HYDROPHILICITY; IRON BINDING CAPACITY; IRON OVERLOAD; LIPOPHILICITY; THALASSEMIA MAJOR; CHEMISTRY; DRUG EFFECT; METABOLISM; ORAL DRUG ADMINISTRATION; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, ORAL; BIOLOGICAL TRANSPORT; CHELATION THERAPY; HUMANS; IRON; IRON CHELATING AGENTS;

EID: 0036428802     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(02)90209-4     Document Type: Review

References (82)

1. Tilbrook GS & Hider RC. Iron chelators for clinical use. In Sigel A & Sigel H (eds) Metal Ions in Biological Systems, pp 691-730. New York: Marcel Dekker, 1998.
2. Hershko C, Konijn AM & Link G. Iron chelators for thalassaemia. British Journal of Haematology 1998; 101: 399-406.
3. Jones MM. The design of therapeutic chelating agents. Journal of Coordination Chemistry 1991; 23: 187-200.
4. Liu ZD & Hider RC. Design of clinically useful iron(III)-selective chelators. Medicinal Research Reviews 2002; 22: 26-64.
5. Hider RC, Liu ZD & Piyamongkol S. The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe(3+) values. Transfusion Science 2000; 23: 201-209.
6. Hider RC, Choudhury R, Rai BL, Dehkordi LS & Singh S. Design of orally active iron chelators. Acta Haematologica 1996; 95: 6-12.
7. Abeysinghe RD, Robert PJ, Cooper CE et al. The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators. Journal of Biological Chemistry 1996; 271: 7965-7972.
8. Liu ZD, Lockwood M, Rose S et al. Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase. Biochemical Pharmacology 2001; 61: 285-290.
9. Hider RC. Nature of non-transferrin bound iron. European Journal of Clinical Investigation 2002; 32 (supplement 1): 50-54.
10. Davis BA & Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95: 1229-1236.
11. Porter JB. Evaluation of new iron chelators for clinical use. Acta Haematologica 1996; 95: 13-25.
12. Travis S & Menzies IS. Intestinal permeability: functional assessment and significance. Clinical Sciences 1992; 82: 471-480.
13. 51Cr-labelled EDTA, L-rhamnose and polyethyleneglycol 400 as probe markers for assessment in vivo of human intestinal permeability. Clinical Science 1986; 71: 71-80.
14. Lipinski CA, Lombardo F, Dominy BW & Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 1997; 23: 3-25.
15. Bergeron RJ, Wiegand J & Brittenham GM. HBED: a potential alternative to deferoxamine for iron-chelating therapy. Blood 1998; 91: 1446-1452.
16. Peter HH, Bergeron RJ, Streiff RR & Wiegand J. A comparative evaluation of iron chelators in a primate model. In Bergeron RJ & Brittenham GM (eds) The Development of Iron Chelators for Clinical Use pp 373-394. London: CRC Press, 1993.
17. Grady RW, Salbe AD, Hilgartner MW & Giardina PJ. Results from phase I clinical trial of HBED. Advances in Experimental Medicine and Biology 1994; 356: 351-359.
18. Pitt CG, Bao Y, Thompson J et al. Esters and lactones of phenolic amino carboxylic acids: prodrugs for iron chelation. Journal of Medicinal Chemistry 1986; 29: 1231-1237.
19. Gasparini F, Leutert T & Farley DL. N,N′-bis(2-hydroxybenzyl)ethylene-diamine-N,N′-diacetic acid derivatives as chelating agents. International Patent WO 95/16663, 1995.
20. Lowther N, Tomlinson B, Fox R et al. Caco-2 cell permeability of a new (hydroxybenzyl)ethylenediamine oral iron chelator: Correlation with physicochemical properties and oral activity. Journal of Pharmaceutical Sciences 1998; 87: 1041-1045.
21. Faller B, Spanka C, Sergejew T & Tschinke V. Improving the oral bioavailability of the iron chelator HBED by breaking the symmetry of the intramolecular H-bond network. Journal of Medicinal Chemistry 2000; 43: 1467-1475.
22. Lattmann R, Acklin P, Buhlmayer P et al. Discovery of ICL670, a novel, orally active iron chelator suitable for clinical development. In Magmano C & Caruso V (eds) 11th International Conference on Oral Chelation in the Treatment of Thalassaemia p 89. Catania, Italy: Tipolitografia Lo Faro Domenico, 2001.
23. Moridani MY, Tilbrook GS, Khodr HH & Hider RC. Synthesis and physico-chemical assessment of novel 2-substituted-3-hydroxypyridin-4-ones, novel iron chelators. Journal of Pharmacy and Pharmacology 2002; 54: 349-364.
24. Hider RC & Hall AD. Clinically useful chelators of tripositive elements. Progress in Medicinal Chemistry 1991; 28: 41-173.
25. Ponka P, Borova J, Neuwirt J et al. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochimica et Biophysica Acta 1979; 586: 278-297.
26. Ponka P, Borova J, Neuwirt J & Fuchs O. Mobilization of iron from reticulocytes. FEBS Letters 1979; 97: 317-321.
27. Cikrt M, Ponka P, Necas E & Neuwirt J. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. British Journal of Haematology 1980; 45: 275-280.
28. Hershko C, Avramovici-Grisaru S, Link G et al. Mechanisms of in vivo chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. Journal of Laboratory and Clinical Medicine 1991; 98: 99-108.
29. Richardson DR & Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. Journal of Laboratory and Clinical Medicine 1998; 131: 306-315.
30. Blaha K, Cikrt M, Nerudova J et al. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood 1998; 91: 4368-4372.
31. Becker E & Richardson DR. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. Journal of Laboratory and Clinical Medicine 1999; 134: 510-521.
32. Edward JT, Ponka P & Richardson DR. Partition-coefficients of the iron(III) complexes of pyridoxal isonicotinoyl hydrazone and its analogs and the correlation to iron chelation efficacy. Biometals 1995; 8: 209-217.
33. Brittenham GM. Pyridoxal isonicotinoyl hydrazone - an effective iron-chelator after oral-administration. Seminars in Hematology 1990; 27: 112-116.
34. Bergeron RJ, Wiegand J, Dionis JB et al. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators. Journal of Medicinal Chemistry 1991; 34: 2072-2078.
35. Baker E, Wong A, Peter H & Jacobs A. Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic. British Journal of Haematology 1992; 81: 424-431.
36. Dexter DT, Ward RJ, Florence A et al. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat. Biochemical Pharmacology 1999; 58: 151-155.
37. Anderegg G & Raber M. Metal complex formation of a new siderophore desferrithiocin and of three related ligands. Journal of the Chemical Society - Chemical Communication 1990; 1194-1196.
38. Wolfe LC. Desferrithiocin. Seminars in Hematology 1990; 27: 117-120.
39. Bergeron RJ, Weimar WR & Wiegand J. Pharmacokinetics of orally administered desferrithiocin analogs in Cebus apella primates. Drug Metabolism and Disposition 1999; 27: 1496-1498.
40. Bergeron RJ, Wiegand J, Weimar WR et al. Desazadesmethyldesferrithiocin analogues as orally effective iron chelators. Journal of Medicinal Chemistry 1999; 42: 95-108.
41. Bergeron RJ, Wiegand J & Brittenham GM. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy. Blood 1999; 93: 370-375.
42. Bergeron RJ, Wiegand J, McManis JS et al. Effects of C-4 stereochemistry and C-′4 hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues. Journal of Medicinal Chemistry 1999; 42: 2432-2440.
43. Bergeron RJ, Wiegand J, McManis JS et al. Hydroxylation of (S)-4,5-dihydro-2-(2-hydroxyphenyl)-4-thiazolecarboxylic acids: a structure-activity study. In World Congress on Iron Metabolism: Biolron 2001: p 66. Cairns, Australia: Queensland Institute for Chemical Research, 2001.
44. Lattmann R & Acklin P. Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators. International Patent WO 97/49395, 1997.
45. Nick HP, Acklin P & Faller B. ICL670A: a new, potent, orally active iron chelator. In Bergeron R, Badman D & Brittenham G (eds) Iron Chelators: New Development Strategies, pp 311-331. Ponte Vedra, FL: Saratoga Publishers, 2000.
46. Hershko C, Konijn AM, Nick HP et al. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 2001; 97: 1115-1122.
47. Nick HP, Wong A, Faller B et al. ICL670A: preclinical profile, pharmacology and iron distribution in rat, comparison with other chelators. In Magmano C & Caruso V (eds) 11th International Conference on Oral Chelation in the Treatment of Thalassaemia, pp 90-91. Catania, Italy: Tipolitografia Lo Faro Domenico, 2001.
48. Alberti D, Sechaud R & Sizer K. ICL670A: update on the clinical development. In Magmano C & Caruso V (eds) 11th International Conference on Oral Chelation in the Treatment of Thalassaemia and Other Diseases, pp 94-96. Catania, Italy: Tipolitografia Lo Faro Domenico, 2001.
49. Porter JB, Singh S, Hoyes KP et al. Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds. Advances in Experimental Medicine and Biology 1994; 356: 361-370.
50. Liu ZD, Piyamongkol S, Liu DY et al. Synthesis of 2-amido-3-hydroxypyridin-4(IH)-ones: novel iron chelators with enhanced pFe(3+) values. Bioorganic Medicinal Chemistry 2001; 9: 563-573.
51. Balfour JAB & Foster RH. Deferiprone - a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs 1999; 58: 553-578.
52. Cohen AR, Galanello R, Piga A et al. Safety profile of the oral iron chelator deferiprone: a multicentre study. British Journal of Haematology 2000; 108: 305-312.
53. Richardson DR. The controversial role of deferiprone in the treatment of thalassemia. Journal of Laboratory and Clinical Medicine 2001; 137: 324-329.
54. Al-Refaie FN, Hershko C, Hoffbrand AV et al. Results of long-term deferipron (LI) therapy: a report of the International Study Group on Oral Iron Chelators. British Journal of Haematology 1995; 91: 224-229.
55. Tricta F & Spino M. Iron chelation with oral deferiprone in patients with thalassemia. New England Journal of Medicine 1998; 339: 1710. (Letter).
56. Hoffbrand AV, Al-Refaie F, Davis B et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91: 295-300.
57. Olivieri NF, Brittenham GM, McLaren CE et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New England Journal of Medicine 1998; 339: 417-423.
58. Tondury P, Zimmermann A, Nielsen P & Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. British Journal of Haematology 1998; 101: 413-415.
59. Kontoghiorghes GJ, Goddard JG, Bartlett AN & Sheppard L. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrinin-4-one. Clinical Pharmacology and Therapeutics 1990; 48: 255-260.
60. Matsui D, Klein J, Hermann C et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clinical Pharmacology and Therapeutics 1991; 50: 294-298.
61. Fassos FF, Klein J, Fernandes D et al. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia. Clinical Pharmacology and Therapeutics 1994; 55: 70-75.
62. Al-Refaie FN, Sheppard LN, Nortey P et al. Pharmacokinetics of the oral iron chelator deferiprone (LI) in patients with iron overload. British Journal of Haematology 1995; 89: 403-407.
63. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. Journal of Medicinal Chemistry 1980; 23: 682-684.
64. Oldendorf WH. Lipid solubility and drug penetration of the blood brain barrier. Proceedings of the Society for Experimental Biology and Medicine 1974; 147: 813-816.
65. Habgood MD, Liu ZD, Dehkordi LS et al. Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability. Biochemical Pharmacology 1999; 57: 1305-1310.
66. Singh S, Epemolu RO, Ackerman R et al. Development of 3-hydroxypyridin-4-ones which do not undergo extensive phase II metabolism. In Bergenon RG & BriHenham G (eds) 3rd NIH-Sponsored Symposium on the Development of Iron Chelators for Clinical Use, p 52. Gainsville, FL: NIH, 1992.
67. Lu SL, Liu ZD, Liu DY & Hider RC. In-vivo metabolism of 1-(3′-hydroxypropyl)-2-methyl-3-hydoxypyridin-4-one (CP41) and 1-(2′-hydroxyethyl)-2-ethyl-3-hydoxypyridin-4-one (CP102) by rat. Journal of Pharmacy and Pharmacology 1998; 50 (supplement): 199.
68. Singh S, Choudhury R, Epemolu OR & Hider RC. Metabolism and pharmacokinetics of 1-(2′-hydroxyethyl)- and 1-(3′-hydroxypropyl)2-ethyl-3-hydroxypyridin-4-ones in rat. European Journal of Drug Metabolism and Pharmacokinetics 1996; 21: 33-41.
69. Zanninelli G, Choudury R, Loreal O et al. Novel orally active iron chelators (3-hydroxypyridin-4-ones) enhance the biliary excretion of plasma non-transferrin-bound iron in rats. Journal of Hepatology 1997; 27: 176-184.
70. Rai BL, Dekhordi LS, Khodr H et al. Synthesis, physicochemical properties and evaluation of N-substituted-2-alkyl-3-hydroxy-4(IH)-pyridinones. Journal of Medicinal Chemistry 1998; 41: 3347-3359.
71. 3+ values. Journal of Medicinal Chemistry 1999; 42: 4814-4823.
72. Rai BL, Liu ZD, Liu DY et al. Synthesis, physicochemical properties and biological evaluation of ester prodrugs of 3-hydroxypyridin-4-ones: design of orally active chelators with clinical potential. European Journal of Medicinal Chemistry 1999; 34: 475-485.
73. Liu ZD, Liu DY, Lu SL & Hider RC. Design, synthesis, and biological evaluation of aromatic ester prodrugs of 1-(3′-hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one (CP41) as orally active iron chelators. Arzneim-Forsch/Drug Research 1999; 50: 461-470.
74. Liu ZD, Liu DY, Lu SL & Hider RC. Synthesis, physicochemical properties and biological evaluation of aromatic ester prodrugs of 1-(2′-hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP102): orally active iron chelators with clinical potential. Journal of Pharmacy and Pharmacology 1999; 51: 555-564.
75. Choudhury R, Epemolu RO, Rai BL et al. Metabolism and pharmacokinetics of 1-(2′-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat. Drug Metabolism and Disposition 1997; 25: 332-339.
76. Piyamongkol S, Liu ZD & Hider RC. Novel synthetic approach to 2-(1′-hydroxyalkyl)- and 2-amido-3-hydroxypyridin-4-ones. Tetrahedron 2001; 57: 3479-3486.
77. Hider RC. Potential protection from toxicity by oral iron chelators. Toxicology Letters 1995; 82: 961-967.
78. Waldmeier PC, Buchle AM & Steulet AF. Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (LI, CP20), in rat brain in vivo. Biochemical Pharmacology 1993; 45: 2417-2424.
79. Hider RC, Singh S & Porter JB. Iron chelating agents with clinical potential. Proceedings of the Royal Society of Edinburgh 1992; 99B: 137-168.
80. Kayyali RS. Analysis of metalloenzyme inhibition by iron chelators developed for the treatment of thalassaemia. PhD thesis: University of London, 1998.
81. Hider RC & Lerch K. The inhibition of tyrosinase by pyridinones. Biochemical Journal 1989; 257: 289-290.
82. Grady RW, Berdoukas VA, Rachmilewitz EA et al. Optimizing chelation therapy: combining deferiprone and desferrioxamine. Blood 2000; 96: 2594. (Abstract).